IQM Quantum Computers to Deliver Quantum Processing Units for the First Spanish Quantum Computer
6.3.2023 12:00:00 EET | Business Wire | Press release
IQM Quantum Computers (IQM), the European leader in quantum computers, announced today it has been selected to deliver quantum processing units for the first Spanish quantum computer to be installed at the Barcelona Supercomputing Center (BSC) and integrated into the MareNostrum 5 supercomputer, the most powerful in Spain.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230306005345/en/
IQM Quantum Computer opened (Photo: Business Wire)
IQM is a member of the consortium led by Spanish companies Qilimanjaro Quantum Tech and GMV that was selected by Quantum Spain, an initiative promoted by the Ministry of Economic Affairs and Digital Transformation through the Secretary of State for Digitalisation and Artificial Intelligence (SEDIA) in December 2022, to build the first quantum computer for public use in Southern Europe.
Dr. Jan Goetz, CEO and Co-founder of IQM Quantum Computers, said, “This is a significant announcement for IQM. We have the right background and experience in developing quantum processors, computers, and national quantum ecosystems. We are looking forward to working with Qilimanjaro Quantum Tech and are delighted to be part of such a strong consortium and play an important role by providing quantum processing units for this notable project.”
The integration of the quantum computer into MareNostrum 5 will have the potential to significantly increase the impact of research and innovation by enabling solutions that complement the capabilities of existing supercomputers, which will be available to the research community, companies, and public organisations, and by strengthening technological and industrial development in Spain and the creation of highly qualified jobs.
“We are delighted to include the expertise of a great player such as IQM to support us developing this innovative system, that will be purely based on Spanish and European technology. We are sure that this will be a very fruitful collaboration and we are looking forward to be partnering with IQM,” said Victor Canivell, Co-founder and CEO of Qilimanjaro.
Jani Heikkinen, Head of Business Development and Country Manager for Spain, said, “This is another example of our European leadership, demonstrating our commitment to advancing the Spanish quantum ecosystem in collaboration with both public and private institutions. Through our office in Madrid, we are also able to provide the necessary support for this project.”
About IQM Quantum Computers
IQM is the pan-European leader in building quantum computers. IQM provides on-premises quantum computers for supercomputing centres and research labs and offers full access to its hardware. For industrial customers, IQM delivers a quantum advantage through a unique application-specific, co-design approach. IQM is building Finland’s first commercial 54-qubit quantum computer with VTT, and an IQM-led consortium (Q-Exa) is also building a quantum computer in Germany. This computer will be integrated into an HPC supercomputer to create a quantum accelerator for future scientific research. IQM has over 240 employees with offices in Singapore, Paris, Madrid, Munich, and Espoo.
About Qilimanjaro
Qilimanjaro Quantum Tech is a deep-tech startup that brings practical applications of quantum computing to the market in a shorter timeframe than digital quantum computers, by using a different but complementary model of quantum computation: the analog model.
Qilimanjaro creates a coherent quantum annealer accessible via our cloud to run real-world applications such as optimisation tasks in the logistics, finance, and energy sector, among others, and quantum simulation of chemical and physical processes, very present in the materials and pharmaceutical research industries. Qilimanjaro aims at providing its clients with a faster, more accurate and sustainable solution to their computing problems.
It has closed significant customer contracts since its first year of operation and has become a key contributor to the European Commission’s AVaQus H2020 project on coherent quantum annealing. Qilimanjaro is a spin-off from the Barcelona Supercomputer Center (BSC), the University of Barcelona (UB) and the Institute of High-Energy Physics (IFAE).
About GMV
GMV is a privately owned technology business group founded in 1984 and trading on a worldwide scale in the following sectors: Space, Aeronautics, Defense and Security, Cybersecurity, Intelligent Transportation Systems, Automotive, Healthcare, Telecommunications and IT for government authorities and major corporations. In 2021, it had revenues of nearly 260 million euros. Working with a staff of over 3,000, the company now runs subsidiaries in Spain, USA, Germany, France, Poland, Portugal, Romania, UK, The Netherlands, Belgium, Malaysia, and Colombia. Seventy five percent of its turnover comes from international projects on all five continents. The company's growth strategy is based on continuous innovation, and it plows back 5% of its turnover into inhouse R&D. GMV has reached CMMI level 5, the world's most prestigious model in terms of enhancing an organization’s process capability, and it has numerous international patents.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230306005345/en/
Contact information
IQM Media Contact
Raghunath Koduvayur, Head of Marketing and Communications
Email: Raghunath@meetiqm.com
Mobile: +65 9353 0048
www.meetiqm.com
Media Contact
Alícia Labián Pagès, Corporate Operations Manager
Email: alicia.labian@qilimanjaro.tech
Mobile: +34 676 683 876
www.qilimanjaro.tech
For more information, please contact:
marketing@gmv.com
www.gmv.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 15:00:00 EEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 15:00:00 EEST | Press release
The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 500 million AGR uranium pellets and 222,000 AGR grids – which is equivalent to burning over 685 tonnes of coal, avoiding the emission of nearly 3 billion tonnes of CO2. Sp
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano ® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 14:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 12:52:00 EEST | Press release
The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not merely a wage dispute. It stems from deep structural concerns regarding the company’s ESG management, lack of operational autonomy, and passive labor relations. Primarily, the union highlighted unresolved corporate governance issues, including allegations concerning unfair labor practices and the unauthorized use of employee personal data, which were prominently reported by South Korea's major broadcaster, MBC, in November 2025. The union believes this crisis stems from management's failure to address r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom